Hackensack, NJ (PRWEB) August 18, 2007
DomaniCell, LLC (DomaniCell), the leading service provider in the field of cell collection, processing, storage and therapies, is now expanding its service to the collection and storage of stem cells and immune system cells for adults who choose to proactively store their cells, while they are healthy and younger, for potential future use.
Collecting and banking one's stem cells and immune system cells is an increasingly important part of a proactive wellness plan. Such a plan is intended to take advantage of the growing number of regenerative and therapeutic treatments currently available and in development that utilize stem cells and cells of the immune system.
When collected and stored from younger and healthier donors, stem cells and immune system cells are more effective than those collected later in life or from a donor suffering from an illness or genetic disorder. Additionally, autologous (self) stem cell and immune system cell replacement has been demonstrated to be highly effective in restoring normal function after exposure to toxins, including radiation.
DomaniCell is part of Progenitor Cell Therapy LLC, a cell therapy development, manufacturing and distribution services company that has been serving the biotech sector since 1998 and has unparalleled experience with all types of cell therapeutic products on the market and in clinical development. Together the companies and their senior management team have performed over 30,000 cell therapy procedures, processed and stored over 18,000 cell therapy products and transported over 14,000 cell therapy products for clinical use in over 5000 patients to-date.
"DomaniCell and Progenitor Cell Therapy together provide an unmatched depth and breadth of experience in the collection, manufacturing, storage and delivery of human cells for clinical use," states Chairman Andrew L. Pecora, MD. "Our group of companies has provided cell therapy manufacturing, storage and delivery services for more patients treated with a cell therapy product than any company in the world. We have developed expertise in over 20 different types of cell-based therapeutics including cell-based therapies for brain and spinal cord repair, cardiovascular disease, diabetes and cancer and other regenerative medicines."
The companies' processing, manufacturing and storage operations are overseen by Dr. Robert A. Preti, President and Chief Scientific Officer of Progenitor Cell Therapy. Dr. Preti is one of the country's leading authorities on cell engineering, has been an active board member of the International Society for Cellular Therapy (ISCT), and has authored numerous papers in the field of cell and tissue processing, cell production and clinical research. He serves as an inspector for the Foundation for Accreditation of Cellular Therapy (FACT) and has served on a number of professional, state and federal regulatory committees charged with the development of accreditation, regulation, and licensure for cellular therapy manufacturing operations.
Also critical to DomaniCell's expertise and offering is unparalleled experience in the apheresis collection of immune system and stem cells under the direction of Dr. Michele Donato, DomaniCell's medical director. Dr. Donato, a recognized clinician and researcher in stem cell transplantation for the past 10 years, joined The Cancer Center at Hackensack University Medical Center after completing her fellowship in medical oncology at the renowned M.D. Anderson Cancer Center at the University of Texas, home of the largest stem cell transplantation program in the world. Dr. Donato is a member of the Foundation for the Accreditation of Cellular Therapy's Standard Oversight Committee and Collection Standards Subcommittee.
"Just as significant," Dr. Pecora continues, "is our approach to stem cell and immune system cell processing and storage. Our company offers the highest industry standard by compliance with FDA's cGMP guidelines, ensuring a therapy-grade cellular product which we believe will be critical to the use of these cells can be used in future cellular therapies. If a person chooses to store their child's umbilical cord blood stem cells or their own stem cells and immune cells, their product deserves processing and storage using the highest manufacturing and regulatory standards."
DomaniCell Chairman, Dr. Andrew L. Pecora, also currently serves as the Chairman and Director of the Cancer Center at Hackensack University Medical Center (HUMC). He is a former member of the Board of Directors of the American Society for Blood and Marrow Transplantation (ASBMT) and a founding member of the International Society for Cellular Therapy (ISCT). He has been an advisor to the National Institutes of Health on stem cell biology and is a recognized international expert in cell therapy.
Earlier this year DomaniCell announced the creation of its Wellness Advisory Board comprised of some of the world's leading clinicians, scientists, and wellness industry experts in areas of relevance to umbilical cord blood, adult stem cell, and immune system cell banking for current and future clinical use.
DomaniCell's Wellness Advisory Board includes Manuel Alvarez, MD, Chairman of Obstetrics and Gynecology at Hackensack University Medical Center and a national broadcaster for Fox News ("Dr. Manny" of Fox News"); Steven A. Goldman, MD, PhD., a leading stem cell scientist for neurodegenerative diseases at the University of Rochester; Malcolm Moore, DPhil, an internationally recognized expert in stem cell biology at Memorial Sloan-Kettering Cancer Center; Bill Parisi, a nationally recognized fitness expert and founder of Parisi Franchise Systems; Jennifer Macleod, a national marketing expert; and Steven Sprague, a patient advocate and stem cell transplant recipient.
On June 13, DomaniCell held a meeting with the Wellness Advisory Board and invited external experts to review a number of issues critical to the provision of stem cell and immune cell banking services, including the definition and quantity of cell types to be collected, the biologic and clinical viability and effectiveness of various types of cells after long-term cryopreservation, the rationale for storing stem cells when younger and healthier for use when older and/or ill, potential future applications for stored stem cells, and educating the public consumer regarding how and why to bank stem cells.
Having launched its national umbilical cord blood banking business in 2006, DomaniCell plans to rapidly expand both DomaniCell's cord blood and adult banking services by leveraging external collaborations and Progenitor Cell Therapy's existing facilities in both New Jersey and California. The company is targeting insurers, multi-national corporations, and pre-identified market niches.
About DomaniCell LLC
DomaniCell LLC is a wholly owned subsidiary of Progenitor Cell Therapy LLC. Launched in 2006, DomaniCell is a national pioneer in the field of stem cell collection and storage, providing innovative family stem cell banking services across the country. DomaniCell's family stem cell banking service brings to clients an opportunity to plan for wellness, regeneration, and treatments for when they may need them most. For more information on DomaniCell and the advantages of its stem cell banking, visit http://www.domanicell.com.
Andrew L. Pecora, MD, Chairman, DomaniCell LLC (201) 883-5308.